Fexaramate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531134

CAS#: 592524-75-9

Description: Fexaramate is a potent, selective farnesoid X receptor agonist.

Chemical Structure

img
Fexaramate
CAS# 592524-75-9
Instruction

Theoretical Analysis

MedKoo Cat#: 531134
Name: Fexaramate
CAS#: 592524-75-9
Chemical Formula: C31H37NO5
Exact Mass: 503.27
Molecular Weight: 503.639
Elemental Analysis: C, 73.93; H, 7.41; N, 2.78; O, 15.88

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fexaramate

IUPAC/Chemical Name: 3-[4-({Cyclohexanecarbonyl-[3-(2-methoxycarbonyl-vinyl)-phenyl]-amino}-methyl)-phenyl]-acrylic acid tert-butyl ester

InChi Key: RNHPBABXWKAHQM-LKRWSQIDSA-N

InChi Code: InChI=1S/C31H37NO5/c1-31(2,3)37-29(34)20-17-23-13-15-25(16-14-23)22-32(30(35)26-10-6-5-7-11-26)27-12-8-9-24(21-27)18-19-28(33)36-4/h8-9,12-21,26H,5-7,10-11,22H2,1-4H3/b19-18+,20-17+

SMILES Code: O=C(OC(C)(C)C)/C=C/C1=CC=C(CN(C(C2CCCCC2)=O)C3=CC=CC(/C=C/C(OC)=O)=C3)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 503.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Panduranga P, Mukhaini M. A rare type of Gerbode defect. Echocardiography. 2011 Jul;28(6):E118-20. doi: 10.1111/j.1540-8175.2010.01356.x. PubMed PMID: 21426390.

2: Nölker G, Sinha AM. Gastroesophageal reflux after RF ablation of AF. Heart Rhythm. 2010 Mar;7(3):e2-3; author reply e3-4. doi: 10.1016/j.hrthm.2009.12.025. PubMed PMID: 20122878.

3: Yang YH, Zheng QS, Li J, Shang FJ, Liu T, Wang HT, Liu XT, Liu L. Age-related changes in the atrial muscarinic type 2 receptor and their effects on atrial fibrillation vulnerability in rabbits. Exp Gerontol. 2009 Sep;44(9):572-8. doi: 10.1016/j.exger.2009.06.002. PubMed PMID: 19539740.

4: Raveloarimisy L, Gras-Champel V, Lemaire-Nanni E, Burde-Hamm F, Andréjak M, Guilbaud JC. [When drug withdrawal for safety concerns may be harmful. A case report with tetrabamate]. Therapie. 2002 Nov-Dec;57(6):593-5. French. PubMed PMID: 12666269.

5: López-Torres E, Lucena MI, Andrade RJ, García Ruiz E, Fernández MC, Peláez G, Soria de la Cruz MJ, Pizarro A. [Tetrabamate-induced hepatotoxicity. Report of seven cases and literature review]. Gastroenterol Hepatol. 2002 Dec;25(10):589-93. Review. Spanish. PubMed PMID: 12459120.

6: Isabel Lucena M, Andrade RJ, García-Ruiz E, Madurga M. [Tetrabamate and a benefit-risk ratio]. Med Clin (Barc). 2002 Apr 6;118(12):477. Spanish. PubMed PMID: 11958767.

7: Severe hepatitis due to Atrium. Prescrire Int. 2001 Oct;10(55):150. PubMed PMID: 11824432.

8: Dumortier J, Bellemin B, Jacob P, Berger F, Chevallier M, Scoazec JY, Vial T. Liver injury due to tetrabamate (Atrium): an analysis of 11 cases. Eur J Gastroenterol Hepatol. 2000 Sep;12(9):1007-12. PubMed PMID: 11007137.

9: Cadranel JF, Di Martino V, Cazier A, Pras V, Bachmeyer C, Olympio P, Gonzenbach A, Mofredj A, Coutarel P, Devergie B, Biour M. Atrium and paroxetine-related severe hepatitis. J Clin Gastroenterol. 1999 Jan;28(1):52-5. PubMed PMID: 9916669.

10: Schneider S, Charles F, Chichmanian RM, Montoya ML, Rampal P. [Acute hepatitis associated with microvesicular steatosis induced by Atrium]. Gastroenterol Clin Biol. 1995 Dec;19(12):1064-5. French. PubMed PMID: 8729422.

11: Cayla JM, Fandi L, Arnould P, Degott C, Gouffier E. [Atrium 300 hepatitis. A new case]. Presse Med. 1995 Nov 18;24(35):1665. French. PubMed PMID: 8545391.

12: Binder D, Jost R, Flury R, Salomon F. [Acute liver failure following tetrabamate]. Schweiz Med Wochenschr. 1995 May 13;125(19):965-9. German. Erratum in: Schweiz Med Wochenschr 1995 Jul 11;125(27-28):1374. PubMed PMID: 7761807.

13: Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol. 1994 Dec;21(6):1075-9. PubMed PMID: 7699230.

14: Rodríguez-Martos A. [Anxiolytic agents in alcoholism]. Aten Primaria. 1994 Mar 31;13(5):260-4. Spanish. PubMed PMID: 7654926.

15: Aubin HJ, Barrucand D, Auzépy P. [Alcohol withdrawal syndrome and delirium tremens. Their treatment]. Rev Prat. 1993 Oct 15;43(16):2064-70. French. PubMed PMID: 8134787.

16: Brocheriou I, Zafrani ES, Mavier P. [Severe acute hepatitis caused by Atrium]. Gastroenterol Clin Biol. 1993;17(4):305-6. French. PubMed PMID: 8339895.

17: Lleonart R, Nomdedeu J, Sambeat MA. [Stevens-Johnson syndrome induced by tetrabamate in a patient with HIV infection]. Med Clin (Barc). 1992 Oct 17;99(12):474. Spanish. PubMed PMID: 1460902.

18: Pariente EA, Mineur D. [Atrium-induced hepatitis with autoimmune pattern]. Gastroenterol Clin Biol. 1992;16(5):485-6. French. PubMed PMID: 1526409.

19: Kuribara H, Tadokoro S. [Behavioral effects of febarbamate (MS-543): evaluation by ambulatory activity, active avoidance and passive avoidance in mice]. Nihon Yakurigaku Zasshi. 1991 Oct;98(4):311-7. Japanese. PubMed PMID: 1802817.

20: Lôo H, Malka R, Hantouche E, Lancrenon S, Guelfi JD. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety]. Encephale. 1991 Jul-Aug;17(4):295-300. French. PubMed PMID: 1959498.